证券日报网讯 12月29日，同享科技发布公告称，公司2025年第三次临时股东会审议通过《关于公司及 全资公司2026年度拟向银行申请综合授信额度的议案》。 （文章来源：证券日报） ...

（文章来源：证券日报） 证券日报网讯 12月9日晚间，同享科技发布公告称，公司于2025年12月9日召开第四届董事会第三次会 议，审议通过了《关于调整2023年股权激励计划行权价格的议案》，将2023年股权激励计划首次授予行 权价格由6.992元/份调整为6.953元/份。 ...

证券日报网讯 12月9日晚间，同享科技发布公告称，公司于2025年12月9日召开第四届董事会第三次会 议，审议通过了《关于注销2023年股权激励计划部分股票期权的议案》。根据公司《2023年股权激励计 划（草案）》的相关规定，4名激励对象已离职，不再符合激励对象条件，上述已获授但未达到行权条 件的合计242，250份股票期权不得行权，由公司注销。 （文章来源：证券日报） ...

Core Viewpoint - The company plans to sell 62% of its subsidiary, Taiyuan Pharmaceutical Co., Ltd., to Shanxi Tongxiang Times Technology Co., Ltd. for RMB 87.19 million, which will enhance asset operational efficiency and provide funding support for business expansion [1] Group 1: Transaction Details - The transaction price for the 62% stake in Taiyuan Pharmaceutical is RMB 87.19 million [1] - After the transaction, Shanxi Tongxiang will hold 95% of Taiyuan Pharmaceutical, while the company will retain a 5% stake [1] - Taiyuan Pharmaceutical will no longer be included in the company's consolidated financial statements post-transaction [1] Group 2: Strategic Rationale - The transaction is based on comprehensive considerations for the company's future development [1] - It aims to improve asset operational efficiency and reduce management costs [1] - The company anticipates an increase in profit of approximately RMB 59 million for the year 2025 following the completion of the transaction (unaudited) [1]

Core Viewpoint - The company plans to sell 62% of its subsidiary, Taiyuan Pharmaceutical Co., Ltd., to Shanxi Tongxiang Times Technology Co., Ltd. for RMB 87.19 million, which will result in a significant change in ownership structure and financial reporting [1] Group 1: Transaction Details - The transaction price for the 62% stake in Taiyuan Pharmaceutical is RMB 87.19 million [1] - After the transaction, Shanxi Tongxiang will hold 95% of Taiyuan Pharmaceutical, while the company will retain a 5% stake [1] - Taiyuan Pharmaceutical will no longer be included in the company's consolidated financial statements following the completion of the transaction [1] Group 2: Strategic Rationale - The transaction is based on comprehensive considerations for the company's future development [1] - It aims to improve asset operational efficiency, reduce management costs, and enhance the company's ongoing operational capabilities [1] - The company anticipates that the transaction will provide financial support for business expansion, with an estimated increase in profit of approximately RMB 59 million for the year 2025 (unaudited) [1]

Core Viewpoint - The company plans to sell 62% of its subsidiary Taiyuan Pharmaceutical to Shanxi Tongxiang Times Technology for a transaction price of 87.1887 million yuan, which will enhance asset operation efficiency and provide funding support for business expansion [1] Group 1 - The transaction will result in Shanxi Tongxiang holding 95% of Taiyuan Pharmaceutical, while the company retains 5% [1] - Taiyuan Pharmaceutical will no longer be included in the company's consolidated financial statements after the transaction [1] - The company estimates that the transaction will increase its total profit by approximately 59 million yuan in 2025 [1]

Core Viewpoint - Yabao Pharmaceutical (SH 600351) announced the transfer of 62% equity in its subsidiary Taiyuan Pharmaceutical to Tongxiang Technology for approximately RMB 87.19 million, aiming to optimize asset structure and improve operational efficiency [1] Group 1: Company Actions - The equity transfer will result in Tongxiang Technology holding 95% of Taiyuan Pharmaceutical, while Yabao will retain 5%, leading to Taiyuan Pharmaceutical being excluded from Yabao's consolidated financial statements [1] - The transaction is part of Yabao's strategy to lower management costs and enhance asset operation efficiency [1] Group 2: Financial Performance - For the year 2024, Yabao Pharmaceutical's revenue composition is as follows: 75.46% from pharmaceutical manufacturing, 21.37% from pharmaceutical wholesale, 1.88% from other trading, and 1.29% from other businesses [1] - As of the report date, Yabao Pharmaceutical's market capitalization stands at RMB 4.8 billion [1]

Core Viewpoint - The company aims to optimize its asset structure and resource allocation, improve asset operation efficiency, and reduce management costs through the transfer of a significant stake in its subsidiary [1] Group 1: Transaction Details - The company signed a share transfer agreement with Tongxiang Technology on November 17, 2025, to transfer 62% of its controlling subsidiary Taiyuan Pharmaceutical for RMB 87.1887 million [1] - After the transaction, Tongxiang Technology will hold 95% of Taiyuan Pharmaceutical, while the company will retain a 5% stake [1] - Taiyuan Pharmaceutical will no longer be included in the company's consolidated financial statements following the completion of this transaction [1]

Core Viewpoint - The company plans to transfer 62% of its stake in its subsidiary, Taiyuan Pharmaceutical Co., Ltd., to Shanxi Tongxiang Times Technology Co., Ltd. for a transaction price of RMB 87.1887 million [1] Group 1 - After the transaction, Tongxiang Technology will hold 95% of Taiyuan Pharmaceutical, while the company will retain a 5% stake [1] - Taiyuan Pharmaceutical will no longer be included in the company's consolidated financial statements following the completion of the transaction [1]

Core Viewpoint - The company plans to transfer 62% of its stake in its subsidiary, Taiyuan Pharmaceutical Co., Ltd., to Shanxi Tongxiang Times Technology Co., Ltd. for a transaction price of RMB 87.1887 million [1] Group 1 - After the transaction, Tongxiang Technology will hold 95% of Taiyuan Pharmaceutical, while the company will retain a 5% stake [1] - Taiyuan Pharmaceutical will no longer be included in the company's consolidated financial statements following the completion of the transaction [1]